Not Yet RecruitingEarly Phase 1

IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

18 participantsStarted 2026-04-30

Plain-language summary

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of IASO207 Injection in patients with Relapsed/Refractory B-cell Malignancies。

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS); high-grade B-cell lymphoma (HGBL);
✓. DLBCL transformed from indolent lymphoma, including transformation from follicular lymphoma (FL) or marginal zone lymphoma (MZL), and DLBCL transformed from CLL/SLL (Richter transformation);
✓. Grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL).
✓. Previous pathological results indicate positive CD19 expression, and/or;
✓. Can provide archived or fresh puncture specimens to the central laboratory for detection to confirm positive CD19 expression.

What they're measuring

Safety endpoint - Adverse Events (AEs)

Timeframe: up to 2 years from IASO207 Injection infusion

Safety endpoint - The incidence of dose-limiting toxicity (DLT)

Timeframe: up to 28 days from IASO207 Injection infusion

Safety endpoint - The types,incidence and severity of abnormal laboratory tests

Timeframe: up to 2 years from IASO207 Injection infusion

Trial details

NCT IDNCT07574346

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-04-30

View on ClinicalTrials.gov More Malignancies trials